SCHEMBL6462222

SCHEMBL6462222

CCCCCC(C)C(=O)Nc1ccccn1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ALOX12 P18054 1/20 0.56
POLB P06746 1/20 0.56
ALDH1A1 P00352 3/20 0.52
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
CTSK P43235 1/20 0.50
FFAR2 O15552 1/20 0.49
NPC1 O15118 1/20 0.49
PKM P14618 1/20 0.49
RAB9A P51151 1/20 0.49
S1PR1 P21453 1/20 0.47
S1PR3 Q99500 1/20 0.47
KDM4E B2RXH2 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21210729 0.84 POLB (0.63) HTTSMN1; SMN2POLBALDH1A1L3MBTL1
SCHEMBL8644189 0.84 TSHR (0.58) HTTSMN1; SMN2ALOX12POLBALDH1A1
SCHEMBL8296133 0.83 HTT (0.53) HTTSMN1; SMN2ALOX12POLBALDH1A1
SCHEMBL21755154 0.80 POLB (0.57) HTTSMN1; SMN2ALOX12POLBALDH1A1
SCHEMBL12352407 0.78 SMN1; SMN2 (0.64) SMN1; SMN2POLBALDH1A1MAPK1LMNA
SCHEMBL10666188 0.77 POLB (0.45) ALOX12POLBALDH1A1MAPK1
SCHEMBL10664841 0.77 POLB (0.45) ALOX12POLBALDH1A1MAPK1
SCHEMBL10663786 0.77 POLB (0.45) ALOX12POLBALDH1A1MAPK1
SCHEMBL7418597 0.77 POLB (0.55) HTTSMN1; SMN2ALOX12POLBALDH1A1
SCHEMBL2666190 0.77 ALDH1A1 (0.71) HTTSMN1; SMN2POLBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493402-B2 Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells DOMPÉ FARMACEUTICI S.P.A. (IT) 2016-11-15 US disclosed
EP-1366018-B1 OMEGA-AMINOALKYLAMIDES OF (R)-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS DOMPÉ FARMACEUTICI S P A (IT) 2016-07-06 EP disclosed
US-20130079514-A1 \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ Dompé S.p.A. (IT) 2013-03-28 US disclosed
US-8288368-B2 inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion DOMPÉ PHA.R.MA S.P.A. (IT) 2012-10-16 US disclosed
US-20050261510-A1 Group 4 metal complexes containing 4-aryl-substituted, tricyclic indenyl derivatives DOW GLOBAL TECHNOLOGIES LLC 2005-11-24 US disclosed
US-20050080067-A1 Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells DOMPE S.P A. (IT) 2005-04-14 US disclosed
CN-1538951-A Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells ��ķ�ɷ����޹�˾ 2004-10-20 CN disclosed
EP-1366018-A1 OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS Dompé S.P.A. (IT) 2003-12-03 EP disclosed
WO-2002068377-A1 OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS Dompé S.p.A. (IT) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080067-A1 Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells C5AR2, C3AR1, C5AR1 HTT 4768/4885SMN1; SMN2 3517/4885ALOX12 232/4885
US-20130079514-A1 \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ C5AR2, C3AR1, C5AR1 HTT 4103/4885SMN1; SMN2 3737/4885ALOX12 246/4885
US-20050261510-A1 Group 4 metal complexes containing 4-aryl-substituted, tricyclic indenyl derivatives COG4, INTS9, SOD1 HTT 3336/4885SMN1; SMN2 4328/4885ALOX12 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.